UPCC 14419: A Phase 1 First in Human Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Enrolling By Invitation
99 years or below
All
Phase
1
1 Location
Brief description of study
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
